Leerink Partnrs Forecasts Increased Earnings for Genmab A/S

Genmab A/S (NASDAQ:GMAB) – Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Genmab A/S in a report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now expects that the company will earn $1.29 per share for the year, up from their previous estimate of $1.15. The consensus estimate for Genmab A/S’s current full-year earnings is $1.29 per share. Leerink Partnrs also issued estimates for Genmab A/S’s Q4 2024 earnings at $0.40 EPS and FY2025 earnings at $1.58 EPS.

A number of other analysts have also recently commented on GMAB. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, October 16th. Redburn Atlantic assumed coverage on Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating for the company. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Stock Down 0.1 %

Shares of NASDAQ:GMAB opened at $23.08 on Monday. The firm has a market capitalization of $15.27 billion, a PE ratio of 22.41, a P/E/G ratio of 0.66 and a beta of 0.99. The company has a 50-day moving average price of $24.39 and a two-hundred day moving average price of $26.39. Genmab A/S has a twelve month low of $21.90 and a twelve month high of $32.89.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 14.73% and a net margin of 23.49%. The firm had revenue of $779.50 million for the quarter, compared to the consensus estimate of $734.60 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its position in shares of Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after buying an additional 544 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Genmab A/S in the first quarter valued at $43,000. Blue Trust Inc. raised its position in Genmab A/S by 892.0% during the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after purchasing an additional 3,880 shares in the last quarter. Headlands Technologies LLC lifted its stake in Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.